To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation

Impact of Oral Controlled Release Flecainide Acetate Capsules on Health-Related QoL in Patients With Paroxysmal Atrial Fibrillation

The purpose of this study is to evaluate the management of paroxysmal atrial fibrillation with controlled release flecainide on patient's quality of life.

Inclusion Criteria:

• In sinus rhythm at treatment initiation
• Experienced symptomatic AF episodes
• Left ventricular ejection fraction of at least 40%
• Females of child bearing potential must be using reliable method of contraception

Exclusion Criteria:

• Intolerance and/or failure of previous therapy with flecainide immediate release
• Currently receiving >200mg/day flecainide immediate release
• Severe symptoms during episodes of arrhythmia
• History of other cardiac conditions/abnormalities
• Heart surgery within the last 2 months
• Renal failure
• Pregnant or lactating females
• Significant extra cardiac or systemic disease
• Abnormal electrolyte levels
• Receiving defined cardiac and/or other treatments